Early Evidence on Tirzepatide Safety and Effectiveness in Organ Transplant Recipients | Research

The takeaway

Tirzepatide showed strong metabolic benefits in organ transplant patients—reducing HbA1c and weight—without compromising graft function or immunosuppressive drug levels.

5.5-6.9 kg weight loss
Transplant recipients on tirzepatide achieved meaningful weight reduction alongside HbA1c improvements

What the researchers found

Across 182 transplant recipients, tirzepatide reduced HbA1c by 0.6-1.4 percentage points and body weight by 5.5-6.9 kg while maintaining stable tacrolimus levels (Δ -0.2 to +0.2 ng/mL) with no rejection signals.

Why it matters

Transplant recipients face heightened metabolic risks but have been largely excluded from GLP-1 drug trials. This early evidence suggests tirzepatide can safely provide metabolic benefits without jeopardizing the transplanted organ.

How the study worked

Narrative review with structured database search identifying 10 reports, with quantitative analysis limited to 6 studies (n=182) providing disaggregated tirzepatide data.

What this study cannot tell us

All included studies are retrospective with small sample sizes. No randomized controlled trials. Long-term graft outcomes and safety data are unavailable. Publication bias toward positive results is possible.

How to read the evidence

Narrative review of retrospective, mostly small studies. Provides early safety signals but lacks the rigor of prospective controlled trials.

When this study was published

Published in 2025, capturing the earliest real-world experience with tirzepatide in transplant populations.

The bigger picture

As GLP-1-based peptide therapies become standard for metabolic disease, understanding their safety in complex patient populations like transplant recipients is essential. This early data opens the door for prospective trials in a group that desperately needs metabolic interventions.

Questions still open

Will prospective randomized trials confirm tirzepatide's safety profile in transplant recipients?
Does tirzepatide offer advantages over semaglutide specifically in the transplant population?
Could the weight loss and metabolic improvements from tirzepatide improve long-term graft survival rates?

Common questions

Why is it important to study tirzepatide in transplant patients specifically?

Transplant patients take immunosuppressive drugs that often worsen diabetes and weight gain. They also face unique risks like organ rejection. Most GLP-1 drug trials excluded transplant recipients, so doctors have had little data to guide treatment decisions.

Does tirzepatide interfere with anti-rejection medications?

This review found that tacrolimus levels remained very stable (changing less than 0.2 ng/mL), suggesting no significant drug interaction. However, close monitoring is still recommended until larger trials confirm this.

Read the original research

Tirzepatide in solid organ transplant recipients: Early real-world signals of efficacy and safety-A narrative review.

Transplantation reviews (Orlando, Fla.), 40(2), 101003

View on PubMed ↗Publisher’s paper ↗

Citation

Corrêa, Lucas Maciel de Almeida; Mazur, Gabriel Rian; Santiago, Clara Belo Gamon; Dante, Letícia Esteves; de Marco, Patrícia Silva; Ferrés, Paola Beatriz Souza. (2026). Tirzepatide in solid organ transplant recipients: Early real-world signals of efficacy and safety-A narrative review.. Transplantation reviews (Orlando, Fla.), 40(2), 101003. https://doi.org/10.1016/j.trre.2026.101003